DMK Pharmaceuticals (LTS:0A4X) Current Accrued Expense : $0.00 Mil (As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is DMK Pharmaceuticals Current Accrued Expense?

DMK Pharmaceuticals's Current Accrued Expense for the quarter that ended in Sep. 2023 was $0.00 Mil.

DMK Pharmaceuticals's quarterly Current Accrued Expense increased from Mar. 2023 ($1.83 Mil) to Jun. 2023 ($2.20 Mil) but then declined from Jun. 2023 ($2.20 Mil) to Sep. 2023 ($0.00 Mil).

DMK Pharmaceuticals's annual Current Accrued Expense increased from Dec. 2020 ($2.71 Mil) to Dec. 2021 ($3.34 Mil) but then declined from Dec. 2021 ($3.34 Mil) to Dec. 2022 ($1.51 Mil).

DMK Pharmaceuticals Current Accrued Expense Historical Data

The historical data trend for DMK Pharmaceuticals's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DMK Pharmaceuticals Current Accrued Expense Chart

DMK Pharmaceuticals Annual Data

Trend

Mar13

Mar14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Current Accrued Expense

Get a 7-Day Free Trial

3.67

2.31

2.71

3.34

1.51

DMK Pharmaceuticals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Current Accrued Expense	Get a 7-Day Free Trial															1.34	1.51	1.83	2.20	-

DMK Pharmaceuticals Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

DMK Pharmaceuticals Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of DMK Pharmaceuticals's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

DMK Pharmaceuticals (LTS:0A4X) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » DMK Pharmaceuticals Corp (LTS:0A4X) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

DMK:USA

Address

11682 El Camino Real, Suite 300, San Diego, CA, USA, 92130

Website

https://www.adamispharmaceuticals.com

DMK Pharmaceuticals Corp Formerly Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.

DMK Pharmaceuticals (LTS:0A4X) Headlines

No Headlines